BTIG downgraded NeoGenomics (NEO) to Neutral from Buy without a price target The company reported another miss and guide down as its structural challenges will take time to fix, the analyst tells investors in a research note. The firm says investors it spoke to are calling into question management’s credibility, which it believes is a fair concern.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics Reports Revenue Growth Amid Rising Losses
- NeoGenomics: Potential Upside Amidst Challenges and Low Valuation
- NeoGenomics: Buy Rating Affirmed Amid Stable Growth and Strategic Focus Despite Near-Term Challenges
- William Blair downgrades NeoGenomics, says rebuilding credibility will take time
- NeoGenomics downgraded to Market Perform from Outperform at William Blair